AXIM Biotechnologies, Inc. filed its 10-K on Apr 17, 2023 for the period ending Dec 31, 2022. In this report its auditor, Russell Bedford Stefanou Mirchandani LLP - RBSM LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.01 USD | -4.49% | -9.09% | -47.37% |
16/04 | AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
15/03 | AXIM Biotechnologies, Inc. announced that it has received $0.814555 million in funding | CI |
1st Jan change | Capi. | |
---|---|---|
-47.37% | 2.78M | |
+26.37% | 48.16B | |
-1.01% | 41.73B | |
+41.82% | 41.03B | |
-5.31% | 28.77B | |
+9.34% | 25.59B | |
-21.69% | 18.96B | |
+6.23% | 12.92B | |
+26.99% | 12.03B | |
-3.38% | 11.77B |
- Stock Market
- Equities
- AXIM Stock
- News AXIM Biotechnologies, Inc.
- AXIM Biotechnologies, Inc. Auditor Raises 'Going Concern' Doubt